首页> 外文期刊>Pharmacology and Therapeutics: The Journal of the International Encyclopedia of Pharmacology and Therapeutics >Research and development of bronchodilators for asthma and COPD with a focus on G protein/K-Ca channel linkage and beta(2)-adrenergic intrinsic efficacy
【24h】

Research and development of bronchodilators for asthma and COPD with a focus on G protein/K-Ca channel linkage and beta(2)-adrenergic intrinsic efficacy

机译:哮喘和COPD支气管扩张剂的研究与开发,重点在于G蛋白/ K-Ca通道连接和β(2)-肾上腺素内在功效

获取原文
获取原文并翻译 | 示例
           

摘要

Bronchodilators are used to improve symptoms and lung function in asthma and COPD. Airway smooth muscle tone is regulated by both muscarinic and beta(2)-adrenergic receptor activity. Large-conductance Ca2+-activated K+ (K-Ca) channels are activated by beta(2)-adrenergic receptor agonists, via G(s), and suppressed by muscarinic receptor antagonists via G(i). This functional antagonism converges on the G protein/K-Ca channel linkages. Membrane potential regulated by K-Ca channels contributes to airway smooth muscle tension via Ca2+ influx passing through voltage-dependent Ca2+ (VDC) channels. The G(s)/K-Ca/VDC channel linkage is a key process in not only physiological effects, but also in dysfunction of beta(2)-adrenergic receptors and airway remodeling. Moreover, this pathway is involved in the synergistic effects between beta(2)-adrenergic receptor agonists and muscarinic receptor antagonists. Intrinsic efficacy is also an important characteristic for both maintenance and loss of beta(2)-adrenergic action. Allosteric modulators of G protein-coupled receptors contribute not only to this synergistic effect between beta(2)-adrenergic and muscarinic M-2 receptors, but also to intrinsic efficacy. The effects of weak partial agonists are suppressed by lowering receptor number, disordering receptor function, and enhancing functional antagonism; in contrast, those of full or strong partial agonists are not suppressed. Excessive exposure to full agonists causes beta(2)-adrenergic desensitization; in contrast exposure to partial agonists does not cause desensitization. Intrinsic efficacy may provide the rationale for the clinical use of beta(2)-adrenergic receptor agonists in asthma and COPD. In conclusion, the G protein/K-Ca linkage and intrinsic efficacy (allosteric effects) may be therapeutic targets for research and development of novel agents against both airway obstruction and airway remodeling. (C) 2015 Elsevier Inc. All rights reserved.
机译:支气管扩张剂用于改善哮喘和COPD的症状和肺功能。毒蕈碱和β(2)-肾上腺素受体活性均调节气道平滑肌的音调。大传导性Ca2 +激活的K +(K-Ca)通道通过β(2)-肾上腺素受体激动剂通过G(s)激活,并通过毒蕈碱受体拮抗剂通过G(i)抑制。这种功能拮抗作用集中在G蛋白/ K-Ca通道连接上。由K-Ca通道调节的膜电位通过通过依赖电压的Ca2 +(VDC)通道的Ca2 +流入而有助于气道平滑肌张力。 G(s)/ K-Ca / VDC通道链接不仅是生理效应的关键过程,而且是β(2)-肾上腺素能受体功能障碍和气道重塑的关键过程。此外,此途径参与β(2)-肾上腺素能受体激动剂和毒蕈碱受体拮抗剂之间的协同作用。内在功效也是维持和失去β(2)-肾上腺素能的重要特征。 G蛋白偶联受体的变构调节剂不仅有助于beta(2)-肾上腺素和毒蕈碱M-2受体之间的这种协同作用,而且还有助于内在功效。降低受体数目,使受体功能紊乱和增强功能拮抗作用可抑制弱的部分激动剂的作用。相反,完全或强的部分激动剂的那些未被抑制。过度暴露于全效激动剂会导致β(2)-肾上腺素脱敏。相反,暴露于部分激动剂不会引起脱敏。内在功效可能为哮喘和COPD中β(2)-肾上腺素能受体激动剂的临床使用提供理论依据。总之,G蛋白/ K-Ca键和内在功效(变构作用)可能是研究和开发针对气道阻塞和气道重塑的新型药物的治疗目标。 (C)2015 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号